FIELD : medicine.SUBSTANCE : invention relates to medicine, namely to oncology, and can be used in the treatment of cancer. Method includes the introduction of cytostatics and a drug based on human exogenous DNA in two phases. At the same time, a cytostatic agent(s) is administered to the patient in the first phase during the first one to three days and then from the next day after the end of the administration of the cytostatic agent(s) and up to 12 days from its onset, the patient is administered the Panagen drug in the form of tablets or capsules containing 5 mg of the active substance, in the amount of 6 tablets/capsules per day, one every 3 hours during the daytime. In the second phase, following the first, for eight, the drug Panagen is administered in the amount of 3 tablets/capsules per day, one every 6 hours during the daytime.EFFECT : use of the invention allows to increase the 5-year recurrence-free survival of patients up to 50?% due to the activation of antigen-presenting dendritic cells and the development of a T-cell adaptive immune response in the first phase of therapy, as well as the activation of Peyer' s patches mononuclear cells of the mucosal immune system and an increase in the level of leukocytes in the second phase of therapy.1 cl, 1 tbl, 6 dwg